<DOC>
	<DOCNO>NCT02082652</DOCNO>
	<brief_summary>Antiretroviral therapy ( medicine use treat HIV ) interact hormonal contraceptive might decrease effectiveness . The single-rod etonogestrel contraceptive implant commonly use low- middle-income country ease insertion removal . Efavirenz nevirapine first-line HIV medicine Sub-Saharan Africa study help determine effective way use medicine etonogestrel implant . The investigator hypothesize woman receive nevirapine- efavirenz-based antiretroviral therapy lower etonogestrel level blood six month insertion compare woman take antiretroviral therapy .</brief_summary>
	<brief_title>A Pharmacokinetic Evaluation Etonogestrel ( ENG ) Implant Antiretroviral Therapy</brief_title>
	<detailed_description>Modern contraceptive use HIV-infected woman prevent pregnancy-related complication economic disparity , also prevent perinatal HIV transmission . Despite clear benefit highly effective modern contraceptive , significant unanswered question safety woman infect HIV , particularly woman anti-retroviral therapy ( ART ) . Currently , non-nucleoside reverse transcriptase inhibitor ( NNRTIs ) , nevirapine ( NVP ) efavirenz ( EFV ) , widely prescribe HIV medication sub-Saharan Africa recently WHO recommend EFV-based ART recommend first-line therapy HIV-1 infect adult , include woman reproductive age . Contraceptive implant become increasingly available popular sub-Saharan Africa , etonogestrel ( ENG ) implant single rod , make insertion removal easier contraceptive implant . The clinical data concurrent use NNRTIs ENG implant limit six case report contraceptive failure set EFV-based ART , highlight potential clinically significant drug-drug interaction . The investigator aim perform pharmacokinetic ( PK ) study evaluate interaction ENG implant NNRTI-based ART . The investigator propose non-randomized , open-label , parallel , three-group , sparse-sampling PK study compare ENG PK parameter control group ( ART ) two treatment group ( EFV- NVP-based ART ) 60 HIV-1 infected woman , 20 woman group . The primary endpoint comparison mean ENG concentration month 6 control group NNRTI treatment group . The investigator hypothesize woman EFV-based NVP-based ART group significantly low mean ENG concentration 6 month post-implant insertion , compare woman control group . The investigator also aim : 1 ) predict disposition ENG woman NNRTI-based ART subsequent 2.5 year intend use PK model ENG concentration beyond 6 month use HIV-infected woman , 2 ) estimate long-term impact chronic ENG exposure EFV NVP concentration measure 6 month combine use , 3 ) compare side-effect frequency ENG subdermal implant woman ART concomitant NNRTI-based ART . The result guide clinician care HIV-infected woman whether use NNRTI-based therapy together ENG implant jeopardize contraceptive efficacy due reduction ENG exposure .</detailed_description>
	<mesh_term>Nevirapine</mesh_term>
	<mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Etonogestrel</mesh_term>
	<mesh_term>Desogestrel</mesh_term>
	<criteria>Evidence personally sign date informed consent document indicate participant inform pertinent aspect study Display willingness ability comply schedule visit , treatment plan , laboratory test , study procedure Age 18 45 year female sex Diagnosis HIV1 infection Desiring ENG subdermal implant contraceptive method Participants yet eligible ART ( base Ugandan Treatment Guidelines ) ; participant receive NVP EFVbased ART minimum 1 month prior screen Participants EFVbased ART must alternative form effective nonhormonal contraception , surgical sterilization copper intrauterine device place For potential participant ART : HIV1 RNA &gt; 400 copies/mL screen visit Serum hemoglobin &lt; 9.0 g/dl Elevations serum level alanine transaminase ( ALT ) 5 time upper limit normal Elevations serum creatinine 2.5 time upper limit normal Use drug know contraindicated ENG , NVP ( woman take NVPbased ART ) , EFV ( woman take EFVbased ART ) within 30 day study entry . Due dynamic nature drug interaction related antiretroviral therapy , study team review concomitant medication screen base US Department Health Human Services drug interaction table . Currently pregnant postpartum &lt; 30 day study entry . Participants must negative urine pregnancy test report unprotected sex since last menstrual period last two week . Concurrent use hormonal contraception ( Note : use form hormonal contraception permissible time study enrollment/insertion ENG implant . Transition form hormonal contraception ENG subdermal implant accommodate accord ENG product labeling . )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Etonogestrel</keyword>
	<keyword>Efavirenz</keyword>
	<keyword>Nevirapine</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>